A thin week: no top-tier-journal acromegaly papers appeared, so Part A draws on the next tier (a radiomics model to predict somatostatin-analog response, a familial Carney-complex case, and bone proteomics), while the rare disease industry's big story is uniQure's four-year Huntington's gene therapy data, which showed a smaller, non-significant benefit and sent the stock down about 40%.
28 Sept 2026
Acromegaly Update — Monday September 28, 2026
A quiet week for top-tier acromegaly literature (four papers, mostly real-world/consensus rather than trial data) paired with a livelier rare disease industry week — a first-ever positive pivotal trial in X-linked retinitis pigmentosa and a new FOP approval that goes head-to-head with Regeneron — while Marea's own MAR002 acromegaly program remains the clearest bridge between the two segments following its merger with Lisata.
21 Sept 2026
Acromegaly Update — Monday September 21, 2026
This week's acromegaly literature centers on long-term disease burden — cardiovascular morbidity, musculoskeletal disease, and precision-medicine treatment selection — while the rare disease industry notched a landmark ultra-rare gene therapy approval, a $1.65B radiopharma merger, and a $123M bet on an oral thyroid eye disease pill.
Reach and audience
Public platform figures. Ratings count people who left a rating, not total listeners.
Apple Podcasts (US)
5.0 / 5
1 ratings
Contact Acromegaly Update
Guest appearances
Does not typically book guests
Based on episode analysis; this does not confirm that the show is currently accepting guests.
Host of Acromegaly Update?
Claim your podcast to manage its listing and keep your show details accurate.
Pod Engine is an independent podcast discovery and analytics service and is not affiliated with or endorsed by this podcast. Artwork and show content belong to their owners. Full legal notice.
Explore this show Podcast research with Pod Engine
